News Image

When you look at NASDAQ:GILD, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

By Mill Chart

Last update: Feb 16, 2024

Take a closer look at GILEAD SCIENCES INC (NASDAQ:GILD), a remarkable value stock uncovered by our stock screener. NASDAQ:GILD excels in fundamentals and maintains a very reasonable valuation. Let's break it down further.

A Closer Look at Valuation for NASDAQ:GILD

ChartMill assigns a Valuation Rating to each stock, ranging from 0 to 10. This rating is calculated by analyzing different valuation elements, such as price to earnings and free cash flow, both in absolute terms and relative to the market and industry. In the case of NASDAQ:GILD, the assigned 7 reflects its valuation:

  • Based on the Price/Earnings ratio of 10.50, the valuation of GILD can be described as reasonable.
  • Compared to the rest of the industry, the Price/Earnings ratio of GILD indicates a rather cheap valuation: GILD is cheaper than 98.48% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 26.56, GILD is valued rather cheaply.
  • The Price/Forward Earnings ratio is 9.94, which indicates a very decent valuation of GILD.
  • 98.82% of the companies in the same industry are more expensive than GILD, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 21.62, GILD is valued rather cheaply.
  • GILD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. GILD is cheaper than 97.63% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of GILD indicates a rather cheap valuation: GILD is cheaper than 98.65% of the companies listed in the same industry.
  • The decent profitability rating of GILD may justify a higher PE ratio.

Exploring NASDAQ:GILD's Profitability

ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NASDAQ:GILD, the assigned 7 is a significant indicator of profitability:

  • GILD's Return On Assets of 9.42% is amongst the best of the industry. GILD outperforms 97.29% of its industry peers.
  • The Return On Equity of GILD (26.33%) is better than 98.31% of its industry peers.
  • GILD's Return On Invested Capital of 13.13% is amongst the best of the industry. GILD outperforms 97.29% of its industry peers.
  • GILD's Profit Margin of 21.45% is amongst the best of the industry. GILD outperforms 97.80% of its industry peers.
  • Looking at the Operating Margin, with a value of 30.16%, GILD belongs to the top of the industry, outperforming 97.80% of the companies in the same industry.
  • Looking at the Gross Margin, with a value of 78.81%, GILD belongs to the top of the industry, outperforming 86.13% of the companies in the same industry.

A Closer Look at Health for NASDAQ:GILD

A critical element of ChartMill's stock evaluation is the Health Rating, which spans from 0 to 10. This rating considers multiple health factors, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:GILD has received a 5 out of 10:

  • GILD has a Altman-Z score of 2.68. This is in the better half of the industry: GILD outperforms 69.54% of its industry peers.
  • The Debt to FCF ratio of GILD is 3.18, which is a good value as it means it would take GILD, 3.18 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of GILD (3.18) is better than 95.26% of its industry peers.

Growth Examination for NASDAQ:GILD

Every stock receives a Growth Rating from ChartMill, ranging from 0 to 10. This rating assesses various growth aspects, including historical and projected EPS and revenue growth. NASDAQ:GILD boasts a 4 out of 10:

  • The Earnings Per Share has grown by an nice 11.13% over the past year.
  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

Every day, new Decent Value stocks can be found on ChartMill in our Decent Value screener.

Our latest full fundamental report of GILD contains the most current fundamental analsysis.

Disclaimer

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

GILEAD SCIENCES INC

NASDAQ:GILD (4/26/2024, 7:00:00 PM)

After market: 65.5 +0.08 (+0.12%)

65.42

+0.15 (+0.23%)

GILD News

News Image5 hours ago - New York TimesU.S. Lags Behind Other Countries in Hepatitis-C Treatment

Despite an arsenal of drugs, many Americans are still unaware of their infections until it’s too late. A Biden initiative languishes without Congressional approval.

News Image2 days ago - Market News VideoJune 7th Options Now Available For Gilead Sciences (GILD)
News Image2 days ago - InvestorPlace3 Dividend Stocks to Buy at a 52-Week Low in April

Explore these three dividend stocks trading near their 52-week lows, presenting compelling opportunities for income-oriented investors.

News Image2 days ago - Gilead Sciences, Inc.FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
News Image3 days ago - The Motley FoolGilead Sciences (GILD) Q1 2024 Earnings Call Transcript

GILD earnings call for the period ending March 31, 2024.

News Image3 days ago - InvestorPlaceGILD Stock Earnings: Gilead Sciences Beats EPS, Beats Revenue for Q1 2024

GILD stock results show that Gilead Sciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

News Image3 days ago - BusinessInsiderGILD Stock Earnings: Gilead Sciences Beats EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gilead Sciences (NASDAQ:GILD) just reported results for the first quarter of 20...

News Image3 days ago - ChartmillCurious about which S&P500 stocks are showing activity after the closing bell on Thursday?

Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top S&P500 gainers and losers in today's after hours session.

News Image3 days ago - Investor's Business DailyWill Gilead's Big Veklury Beat Offset A Cancer Drug Miss?

Gilead beat first-quarter calls, but it came on the back of Covid drug Veklury.

News Image3 days ago - Gilead Sciences, Inc.Gilead Sciences Announces First Quarter 2024 Financial Results
News Image3 days ago - Market News VideoNoteworthy Thursday Option Activity: NEM, GILD, GOOG
News Image11 days ago - ChartmillWhy the dividend investor may take a look at NASDAQ:GILD.

Uncovering Dividend Opportunities with GILEAD SCIENCES INC (NASDAQ:GILD).

GILD Links
Follow us for more